Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fuli Wang, Teng Xia, Zhiqiang Li, Xuzhu Gao, Xinjian Fang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-09-01
Edice:	Frontiers in Oncology
Témata:	non-small cell lung cancer immune checkpoint inhibitors CTLA-4 PD-1 PD-L1
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1213297/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!